Toby Maher, MD
Enriched profileProfessor of Clinical Medicine, Director of Interstitial Lung Disease · Keck School of Medicine of the University of Southern California (USC)
Toby Maher is Professor of Clinical Medicine, Director of Interstitial Lung Disease at Keck School of Medicine of the University of Southern California (USC). OpenAlex indexes 944 publications with 35,184 citations (h-index 96); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Toby Maher, MD, is Professor of Clinical Medicine, Director of Interstitial Lung Disease at Keck School of Medicine of the University of Southern California (USC). The public record shows 944 publications with 35,184 citations (h-index 96), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2025–2025).
- Most recent indexed publication: 2026 · The European respiratory journal
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 109 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 307.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ipf-summit.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Rein Therapeutics
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Sponsor: Avalyn Pharma Inc.
Industry payments
Updated 27 Aug 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20253 payments$101,816openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year202543 payments$86,964openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202518 payments$26,383openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.5%Kinase inhibitor27.3%Ofev100%Part D≥60 patientsPyridone9.2%Pirfenidone79%Esbriet22%Part D<11 patientsMetabolism & gastrointestinal
23.7%Corticosteroid22.7%Prednisone100%Part D≥120 patientsProton pump inhibitor1.1%Omeprazole100%Part D<11 patientsRespiratory
14.7%Corticosteroid6.7%Trelegy Ellipta37%Breyna24%Breo Ellipta24%Budesonide-Formoterol Fumarate15%Part D<11 patientsbeta2-Adrenergic Agonist5.6%Albuterol Sulfate Hfa100%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Pre-clinical development of a small molecule therapeutic for the systemic treatment of idiopathic pulmonary fibrosis
University of Southern California
FY2025$943,301UG3AG097137
Congress activity
Updated 27 Aug 2026
2 congress contributions (2017) across AMCP per OpenAlex. The most recent:
- Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
AMCP Meeting
AMCP2017Co-author - Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension
AMCP Meeting
AMCP2017Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets.
The European respiratory journal
Letter2026 - Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
The European respiratory journal
Clinical Trial2026 - Progressive pulmonary fibrosis: the importance of identification and intervention.
European respiratory review
Review2026 - A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults.
ERJ open research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease1,620 citations2019
- 02
- 03Interstitial Lung Disease in Systemic Sclerosis1,194 citations2008
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/toby-maher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Toby-Maher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/toby-maher-00b71530
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DQpa6OSDZtv
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/toby-maher-md-msc-phd-rethinking-pulmonary-fibrosis/id946943193
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →keckmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
American Journal of Respiratory and Critical Care Medicine (AJRCCM)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →atsjournals.org ↗ - Editorial/International Advisory Board
The Lancet Respiratory Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thelancet.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
National Heart and Lung Institute, Imperial College London (Fibrosis Research Group, Inflammation, Repair and Development Section)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Medical Advisor / Advisor
NeRRe Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Medical Advisor
Lung Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviews
press, podcasts and appearances- Medscape InDiscussion podcast
Season 1 Episode 6: "Now Unfolding: The Future of Idiopathic Pulmonary Fibrosis" (with Dr. Jeffrey Swigris)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗ - Rheumatology Advisor podcast: "The Breath-Taking Lungs and Scleroderma"
interview on prevalence of lung involvement in scleroderma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatologyadvisor.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.